Proteina Co., Ltd. (468530)

Overview

Proteina Co., Ltd. is a biotechnology company dedicated to enhancing healthcare through innovative protein-protein interaction (PPI) analysis. Established in 2015 and based in Seoul, South Korea, the company focuses on pioneering single-molecule co-immunoprecipitation (SMCIP) technology. This advanced platform allows for precise measurement and profiling of PPIs at a highly detailed level. With its proprietary technology, Proteina Co., Ltd. is instrumental in identifying novel disease biomarkers and therapeutic targets, thereby accelerating disease diagnostics and drug discovery processes.

The technology offered by Proteina Co., Ltd. provides accurate and reproducible data on PPIs, enabling the integration of complex datasets from various sources and timelines. This capability is essential in facilitating translational research and clinical applications. The company's contributions are particularly significant in the pharmaceutical and biotech sectors, with a focus on oncology, where real-time analysis of signaling pathways informs targeted therapy decisions and guides drug resistance profiling.

Proteina Co., Ltd. stands at the forefront of advancements in personalized medicine and biomarker-driven research, playing a critical role in the evolving landscape of biotechnology and medical research.

Products and Services

• Single-Molecule Co-Immunoprecipitation (SMCIP) Technology:

  This proprietary technology provides a groundbreaking approach to measure and profile protein-protein interactions. It enables researchers to analyze PPIs with high granularity, which is vital for understanding complex biological systems and disease mechanisms.

• Disease Biomarker Identification Services:

  Proteina Co., Ltd. offers services aimed at identifying novel biomarkers associated with various diseases. By utilizing SMCIP technology, the company can reveal potential therapeutic targets, enhancing the ability to diagnose conditions more accurately.

• Therapeutic Target Discovery Platform:

  The company specializes in discovering new therapeutic targets for drug development. This platform combines PPI data with advanced algorithms, streamlining the process of finding effective targets for drug interventions.

• Translational Research Support:

  Proteina Co., Ltd. provides essential support for translational research by integrating diverse datasets. This service is critical for bridging the gap between laboratory findings and clinical applications, ensuring that research translates effectively into real-world medical solutions.

• Oncology Solutions:

  The company focuses on developing targeted therapies in oncology. By utilizing real-time analysis of signaling pathways, Proteina Co., Ltd. aids in informing treatment decisions and understanding drug resistance mechanisms, ultimately supporting personalized treatment strategies.